Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Divestments (2022 - 2023)

VYNE Therapeutics (VYNE) has disclosed Divestments for 2 consecutive years, with $5.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Divestments fell 68.26% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Dec 2023, down 68.09%, and an annual FY2023 reading of $5.0 million, down 68.09% over the prior year.
  • Divestments was $5.0 million for Q1 2023 at VYNE Therapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Divestments topped out at $15.8 million in Q1 2022 and bottomed at -$86000.0 in Q3 2022.